June 20, 2025

FDA Approves First Twice-Yearly Injectable PrEP

FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.

Conexiant

June 20, 2025

Multiple Biological Drivers Identified in Hair Graying

New research identifies oxidative stress, DNA damage, genetic variants, and stem cell depletion as key drivers of hair graying, with emerging therapies under investigation.

Conexiant

June 18, 2025

Are CBD Compounds Effective Antifungals?

CBD and CBDV exhibit antifungal activity against Cryptococcus neoformans and dermatophytes in vitro and improve survival in an in vivo model.

Conexiant

June 17, 2025

FMT as First-Line CDI Treatment?

New randomized trial shows fecal microbiota transplantation may reduce antibiotic dependence in first-episode infections

Conexiant

June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 05, 2025

Conservative Mental Health Study Faces Retraction

Scandinavian Journal of Psychology retracts study on conservatism and mental health, citing methodological flaws and biased language despite authors' objections.

Conexiant

June 04, 2025

Dog Exposure May Lower Genetic Eczema Risk

A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.

Conexiant